via NEWMEDIAWIRE -- Orion Nutraceuticals Inc., (CSE: ORI) (the
“Company” or “Orion”) a cannabis life science company, is pleased
to announce continued milestone advancement by its Colombian-based
strategic ally and supply partner, FCM Global S.A.S. (“FCM”).
Orion benefits from FCM’s ability to supply low-cost, high-quality
extracts, enabling Orion to win sizable long-term purchase orders
for their finished products from top-tier international clients,
including retailers, wholesalers, homeopathic and pharmaceutical
sales channels, and world-class sports organizations.
FCM Global, a producer and supplier of cannabis extracts, full
spectrum oils, CBD isolates, and microemulsions, has begun its
final large-scale planting phase at its La Ceja, Colombia
cultivation greenhouse, following a sequence of successful test
harvests. With a capacity of over 40,000 plants, FCM’s indoor
greenhouse is a fully enclosed and tightly controlled environment
which is operated to GAP standards. Supplemental lighting,
irrigation, nutrition, humidity, plant health, and pest management
are all systematically monitored in real-time and managed by FCM’s
team of experienced agronomists.
By combining modern agro-tech methods with Colombia’s equatorial
climate, 12/12/365 light cycle, abundant natural resources and La
Ceja’s 7,200 ft elevation, which provides optimal rainfall,
drainage, and temperature, FCM will realize the equivalent of 3-4
harvests per year and has achieved a production cost from clone to
dried flower of under US 4¢ per gram.
FCM is also in the final stage of Q1 2019 completion for its
centralized La Ceja extraction laboratory. Integrating proven
ethanol-based methods with the latest ultrasonic and molecular
distillation technologies, the streamlined FCM extraction lab will
flexibly produce a range oils and isolates in industrial yields at
an all-in direct production cost for full spectrum oil of under US
45¢ per gram.
“FCM Global’s Co-Source Colombia model complements Orion
Nutraceuticals’ downstream product development focus, providing
critical low-cost inputs without compromising consistency, quality,
or traceability. For the cannabis industry to reach its full
potential, it must develop innovative consumer and patient products
that are safe, affordable, non-addictive, readily available, and
add value over traditional alternatives,” said Jonathan Fiteni, CEO
of Orion. “Each of these requirements are key strengths of Orion
and areas which FCM Global is well-positioned to support through
their unique high-CBD strains and efficient soil-to-oil
platform.”
Collaborating in partnership with Orion, FCM continues to
execute a clearly defined multi-phase expansion strategy to extend
their first mover advantage in Colombia. FCM has secured
significant additional prime agricultural land suitable for
industrial-scale cultivation, extraction, and distribution.
By 2021, FCM expects to produce over 185 tons of dried flower per
annum, in 1.8 million square feet of cultivation space, and more
than 27 tons of cannabis oil.
“FCM Global was founded on two beliefs. The first, which
we have in common with Orion, is that cannabinoids represent the
medical science market of the future, with the potential to improve
millions of lives and offer a compelling alternative to
conventional pharmaceutical, medicine, and wellness options,” said
Carlos Velasquez, CEO of FCM Global. “The second belief is
that Colombia may well be the best place on Earth to sustainably
produce high-quality cannabis inputs at large scale and low
cost. FCM Global is proud to be Orion’s trusted supply
partner as they evolve and expand their product line of cannabinoid
extracts and oils, nutraceuticals, pharmaceuticals, and sports
therapies for international distribution.”
About Orion Nutraceuticals Inc. Orion Nutraceuticals Inc. aims
to set a new standard in cannabis life science by producing and
developing innovative products with key strategic partners in the
industry. In conjunction with its professional sports strategic
alliances, the company is poised to advance research and
development in the plant science sector, deliver science-based
products and services, and market CBD therapies to the mainstream
with proprietary brands and products. Medic-Oasis, Orion’s
subsidiary, has submitted its application for an ACMPR license and
is currently under review with Health Canada. Build out is expected
to begin in Q1 2019, with completion of the 30,000 square foot
facility expected by Q3 2019. Orion Nutraceuticals is partners with
Colombian based medical cannabis corporation FCM Global. FCM
supplies pharmaceutical, nutritional, wellness, and cosmetic
companies in legal markets worldwide with customized medical
cannabis extracts, oils, and isolates at commercial scale. Orion
shares trade in Canada on the CSE under the symbol ORI.
About FCM Global S.A.S. FCM Global S.A.S. is a
fully licensed Colombian medical cannabis company producing a range
of full spectrum oils, CBD isolates, and micro-emulsions in support
of finished goods manufacturers in legal markets worldwide.
Headquartered in Medellin, with a 235,800 ft2 production facility
in La Ceja, the FCM Global platform encompasses genetics,
cultivation, extraction, quality testing, formulation, and
distribution. FCM Global's "Co-Sourced Colombia" model
reliably delivers lower production costs and high-quality inputs at
scale to its clients in the nutritional, wellness, pharmaceutical,
and research sectors. FCM Global will soon break ground on
FCM Tolima, a planned 450 hectare cultivation and production site
which will produce over 1,000 tons of cannabis oil at full
capacity. Please see www.fcm-global.com for
additional information.
ON BEHALF OF THE ORION BOARD
Jonathan Fiteni, CEO Orion Nutraceuticals Inc.
www.orionnutra.ca
Investor Relations Robin Linden, Director
1.604.313.2768 investors@orionnutra.ca
This news release may contain forward-looking
statements based on assumptions and judgments of management
regarding future events or results. Such statements are subject to
a variety of risks and uncertainties which could cause actual
events or results to differ materially from those reflected in the
forward-looking statements. The company disclaims any intention or
obligation to revise or update such statements. For a description
of the risks and uncertainties facing the Company and its business
and affairs, readers should refer to the Company’s Management’s
Discussion and Analysis and other disclosure filings with Canadian
securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to
sell or solicitation of an offer to buy any of the securities
described herein and accordingly undue reliance should not be put
on such. Neither the Canadian Securities Exchange (CSE or CNSX
Markets), nor its Regulation Services Provider (as that term is
defined in policies of the CSE), accepts responsibility for the
adequacy or accuracy of this release. This news release does not
constitute an offer to sell or a solicitation of an offer to buy
any of the securities described herein in the United States. The
securities described herein have not been registered under the
United States Securities Act of 1933, as amended (the “U.S.
Securities Act”), or any state securities law and may not be
offered or sold in the “United States”, as such term is defined in
Regulation S promulgated under the U.S. Securities Act, unless
registered under the U.S. Securities Act and applicable state
securities laws or an exemption from such registration requirements
is available.
Old Republic (NYSE:ORI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Old Republic (NYSE:ORI)
Historical Stock Chart
From Apr 2023 to Apr 2024